Consumer model
Ottava
By Johnson & Johnson · surgical
- Price
- —
- Availability
- Internal use only (not for retail).
- Maturity
- research
- Real-world use
- No verified deployments
J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred. By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.
Readiness
Ottava is internal use only (not for retail), no capability claims are on file, the model has no verified field deployments in the registry, and no incidents are on record.
- Availability
- internal-only
Internal use only (not for retail).
- Price honesty
- no-price
No price points on file for Ottava.
- Capability honesty
- no-claims
No reviewed capability claims on file for Ottava.
- Real-world use
- research
Maturity: research. No verified deployments in the registry.
- Safety record
- no-incidents
No incidents on record. No verified deployments either.
What it claims to do
No reviewed capability claims on file.
Price
No reviewed price points on file.
Real-world use
No verified deployments on file for Ottava.
Safety record
No incidents on record. No verified deployments either, so the absence is uninformative.
Privacy
No privacy practices disclosed or on file for Ottava.
Specs
- notes
- [{"label":"Verified (pre-market)","value":"Johnson & Johnson (NYSE: JNJ; founded 1886, New Brunswick NJ; MedTech/Ethicon division) submitted Ottava to the FDA via a De Novo classification application on Jan 7 2026 for multiple upper-abdomen general-surgery procedures. J&J's own language: Ottava 'is under development and is not authorized to be marketed or sold in any market.' IDE first cases completed early 2025 at Memorial Hermann-Texas Medical Center; a second IDE (inguinal hernia) approved late 2025."},{"label":"Maturity = research (FDA gating not cleared)","value":"Per the framework, NO clearance = research-tier regardless of corporate scale or demos. Ottava has an active IDE and a pending De Novo submission but no clearance and ZERO installed base / zero approved procedures (IDE-trial cases only)."},{"label":"Aggregator-drift correction","value":"A secondary source claimed Ottava was 'targeted for commercial launch late 2025 / early 2026.' CONTRADICTED by the primary J&J source (De Novo submitted Jan 7 2026; explicitly not marketable). Do NOT register a launch date. 'Breakthrough device designation' (secondary) is unverified against primary records."},{"label":"Adjacent J&J robotics (context, not this entity)","value":"Monarch (robotic bronchoscopy, via the 2019 $3.4B Auris acquisition; FDA-cleared; competes with Intuitive Ion) and Velys (robotic knee replacement, FDA-cleared Mar 2021) are separate commercial J&J robotics products."}]
- products
- Ottava: J&J MedTech (Ethicon) soft-tissue general-surgery robotic platform, four arms integrated into the operating table; announced 2020. NOT cleared, NOT marketed.
- formFactor
- surgical (unified-architecture four-arm soft-tissue general-surgery robot; arms integrated into the table)
What's under the hood
No brain on file for Ottava.
Frequently asked questions
- Is the Ottava actually available for purchase?
- Not available to consumers. In internal use by Johnson & Johnson.Source: J&J submits Ottava to FDA (De Novo, Jan 7 2026; 'not authorized to be marketed')
- What does the Ottava cost?
- Not announced.
- Where is the Ottava being used?
- No verified field deployments on record.
- Is the Ottava safe?
- No incidents on record, but with no verified field deployments either, the absence is uninformative.
- How does the Ottava handle privacy?
- No privacy practices disclosed or on file for Ottava.
- Who makes the Ottava?
- Ottava is made by Johnson & Johnson, based in New Brunswick, New Jersey, USA.Source: J&J submits Ottava to FDA (De Novo, Jan 7 2026; 'not authorized to be marketed')
Manufacturer
Johnson & Johnson (registry record: /companies/johnson-and-johnson)
Compared to
- Hugo RASby Medtronic · surgical
- da Vinci (and Ion)by Intuitive Surgical · surgical
Sources
- J&J submits Ottava to FDA (De Novo, Jan 7 2026; 'not authorized to be marketed') · https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
- J&J robotics layoffs + Ottava delays (history/context) · https://www.medtechdive.com/news/jnj-layoffs-auris-california-robotic/644544/
- J&J takes over Verb Surgical (Ottava lineage) · https://www.fiercebiotech.com/medtech/jj-to-take-over-verb-surgical-its-robotics-venture-verily
Machine-readable: this page as markdown.
Canonical: https://deploy.report/models/jnj-ottava